Welcome to BioSeeker Group!

Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 7005
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies.

    To find out more about Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part II: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
4SC
A&G Pharmaceutical
AB Science
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
ACT Biotech
Actinium Pharmaceuticals
Active Biotech
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Agennix
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allist Pharmaceuticals
Allostera
Alnylam
AlphaVax
ALSP
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisoma
Aphios
Apogee Biotechnology
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
Avila Therapeutics
Bavarian Nordic
Bayer
Benitec
Berkeley Lab
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Bionovo
Biosceptre
Biotecnol
Biotest
Biotica Technology
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Innovations
Cancer Research Technology
Catalyst Biosciences
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Cellmid
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CerRx
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
CSL
Cue Biotech
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokine PharmaSciences
Cytopia
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dompe
Dr Reddy’s
Dyax
Eisai
Elan
Elara Pharmaceuticals
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
Ergon Pharmaceuticals
Erimos
EUSA Pharma
Exelixis
ExonHit Therapeutics
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galapagos
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GenPat77
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
GPC Biotech
Green Cross
Hanmi
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hy BioPharma
Hypha Discovery
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intellikine
Intracel
Introgen Therapeutics
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAI Pharmaceuticals
Kaketsuken
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
Kissei
Kringle Pharma
KuDOS
Kyowa Hakko Kirin
Kyto Biopharma
Lee’s Pharmaceutical
Leo
Lexicon Pharmaceuticals
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
Marina Biotech
MAT Biopharma
MaxoCore Pharmaceuticals
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Morvus Technology
Mycenax
Myrexis
Nano Terra
Neovacs
Nerviano Medical Sciences
Neuren
NewSouth Innovations
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
NovaLead
Novartis
Novelix
Novogen
Noxxon
Oasmia
Oncalis
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Onyvax
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanGenetics
Pathway Therapeutics
Patrys
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacopeia
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Prima Biomed
Proacta
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progen
Progenics Pharmaceuticals
Protein Sciences
Protgen
Provid
PTC Therapeutics
QLT
Quantum Pharmaceuticals
Ramot
Ras Therapeutics
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Rexahn
Rigel
Samtheo Biopharma
Sanofi
Santaris Pharma
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
SciClone Pharmaceuticals
Seattle Genetics
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Shanghai CP Guojian
Shenogen
Shionogi
Silence Therapeutics
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
Sunesis
Sunol Molecular
SuperGen
SuppreMol
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Tamir Biotechnology
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
TeGenero
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Wilex
VioQuest
Viragen
ViroMed
Viventia Biotech
Wyeth
XBiotech
Xcovery
Xencor
Xerion
Xoma
Y’s Therapeutics
YM BioSciences
Zenotech
Zenyaku Kogyo
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
ABT-510
AC-480
adecatumumab
AE-37
AF-802
afatinib
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
alvocidib
amatuximab
AME-133
AMG-386
Angiozyme
apatinib
AR-42
ARQ-197
AT-7519
AT-9283
atrasentan
AV-299
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belimumab
bevacizumab
BEZ-235
BGT-226
BHQ880
BI-811283
BIBF-1120
blinatumomab
BMS-663513
BMS-690514
BMS-754807
BMS-777607
BMS-936558
bosutinib
brentuximab vedotin
brivanib alaninate
BT-062
Cabozantinib
CAL-101
carlumab
catumaxomab
CBP-501
CC-223
CDX-1307
CDX-1401
cediranib
cetuximab
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
crizotinib
CT-011
dacomitinib
dalotuzumab
danusertib
daratumumab
dasatinib
denosumab
DI-17E6
dinaciclib
dovitinib lactate
E-75
E-7820
elotuzumab
EMD-273063
EMD525797
endostatin
endoxifen
ENMD-2076
enzastaurin hydrochloride
epratuzumab
epratuzumab-Y90
erlotinib
ertumaxomab
everolimus
Exherin
farletuzumab
figitumumab
foretinib
fosbretabulin tromethamine
fostamatinib disodium
fresolimumab
galiximab
ganitumab
gefitinib
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GliaAtak
GS-6634
GSK-2118436
GT-111
HBP-347
I-131-labetuzumab
ibritumomab tiuxetan
IC-83
icrucumab
idronoxil
imatinib mesilate
INCB-028060
inotuzumab ozogamicin
INSM-18
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
JI-101
KD032
KX2-391
L19-TNFalpha
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY-2090314
LY-2275796
LY2495655
lymphomun
MABp1
mapatumumab
masitinib
MCS-110
MEDI-551
MEDI-573
MGCD-265
midostaurin
milatuzumab
milatuzumab-doxorubicin
MK-1775
MKC-1
MLN-8237
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
motesanib diphosphate
moxetumomab pasudotox
muparfostat (IV)
MVA-BN Her-2 vaccine
naptumomab estafenatox
natalizumab
necitumumab
neratinib
NGR-TNF
nilotinib
nimotuzumab
NPB-001-056
obinutuzumab
ofatumumab
olaratumab
ON-01910
onartuzumab
Onyvax-105
oregovomab
OSI-027
OTS-102
P276-00
paclitaxel
PancAtak
panitumumab
PAT-SC1
pazopanib hydrochloride
PCI-27483
PD-0332991
pegdinetanib
perifosine
pertuzumab
PF-4856884
PHA-848125AC
plitidepsin
ponatinib
ProstAtak
PTC-299
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
Reditux
regorafenib
RG-7160
ridaforolimus
rilotumumab
rituximab
robatumumab
romiplostim
ruxolitinib
RX-0201-N
samalizumab
SAR-3419
SCH-900776
seliciclib
siltuximab
sirolimus
sorafenib tosylate
sotatercept
ß-lapachone
SU-6668
sunitinib malate
Sym-004
talactoferrin alfa
talmapimod
tandutinib
TAS-102
tasquinimod
TB-403
telatinib
temsirolimus
Tenarad
terameprocol
thymalfasin
tigatuzumab
tipifarnib
tivozanib
tocilizumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
vandetanib
varlitinib
veltuzumab
vemurafenib
vismodegib
volasertib
volociximab
vosaroxin
XL-147
XL-184
XL-281
XL-413
XL-647
XL-765
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies.
    To find out more about Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Pancreatic Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Pancreatic Cancer and by the mechanism/target/effect of Angiogenesis. Learn More


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Breast Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Triple Analysis: Leukemia, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Leukemia, Lymphoma and Prostate Cancer. Learn More